Story perspectives

Intellia's Lonvo-z Cuts Attacks 87% in Phase 3, BLA Filed

4/27/2026

Summary

Intellia Phase-3 Success

Intellia Therapeutics announced positive Phase 3 results for lonvo-z and filed a biologics license application to the FDA.
A 50 mg infusion reduced attacks by 87% versus placebo, lowering the monthly rate to 0.26 from 2.10.
62% of patients remained attack-free and off therapy for months versus 11% placebo, with only mild/moderate reactions and no serious events.
Shares rose 25% before the April 27 2026 release, fell 3% after, with market cap near $1.61 billion.

Summary

Intellia Eyes $500M

Analysts project lonvo-z could reach peak annual sales of up to $500 million.
The therapy will compete with about a dozen chronic HAE drugs and recent FDA approvals.
Intellia shares rose 5% as investors praised the clean safety profile.
Lonvo-z, the first in-vivo CRISPR therapy, has efficacy said to rival CSL’s Andembry.

1 of 2

Intellia Phase-3 Success

Intellia Therapeutics announced positive Phase 3 results for lonvo-z and filed a biologics license application to the FDA.
A 50 mg infusion reduced attacks by 87% versus placebo, lowering the monthly rate to 0.26 from 2.10.
62% of patients remained attack-free and off therapy for months versus 11% placebo, with only mild/moderate reactions and no serious events.
Shares rose 25% before the April 27 2026 release, fell 3% after, with market cap near $1.61 billion.

1 / 2